Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137332 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00137332: Clinical Trial Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00137332 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137332, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
Interventions
- DRUG GAP-486 (ZP-123)
- DRUG 0.9% Sodium Chloride, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Why NCT00137332 stopped before completion
NCT00137332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which GAP-486 (ZP-123) is the first listed.
NCT00137332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00137332 about?
NCT00137332 is a clinical study titled "Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease". The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
What is the current status of trial NCT00137332?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00137332?
The interventions under investigation include: GAP-486 (ZP-123) (DRUG), 0.9% Sodium Chloride, USP (DRUG).
Who is sponsoring clinical trial NCT00137332?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00137332's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia